Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ryzodeg vs NovoMix 30 in Type 2 Diabetes (BOOST: Intensify Premix 1)
NCT01009580Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2009
- Primary completion
- Aug 2010
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at 26 weeks. Started Nov 2009; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01009580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01009580.